Our abovementioned results indicate that the LRrisk scoring model may serve as a predictive biomarker for immunotherapy of NSCLC, within which POPDC3 is significantly overexpressed in NSCLC and correlates with poor prognosis of NSCLC patients. This evidence concerns the gene POPDC3 and non-small cell lung carcinoma.